Loading organizations...
§ Private Profile · Menlo Park, CA, USA
clinical-stage biopharmaceutical company developing small molecule drugs for cardiovascular diseases, anticoagulation, and atrial fibrillation.
Founded in 2011 by Peter Milner, M Ken Kengatharan, and Pascal Druzgala, Armetheon was a Menlo Park, California clinical stage biopharmaceutical company developing novel small molecule therapeutics for cardiovascular diseases. The pre-revenue enterprise focused on advancing proprietary drug candidates through clinical trials, targeting thrombosis, atrial fibrillation, and mechanical heart valve disease with its lead oral anticoagulant, tecarfarin. Under CEO Sanjay Kakkar, the biotechnology firm raised $31.3 million in total venture funding, including a $7 million Series A in 2014 and a $24 million Series B in 2015. This financial backing was secured from institutional investors such as AshHill Biomedical Investments, Atheneos Capital, and Hercules BioVentures Partners to fund pivotal clinical trials. In April 2017, the organization executed a strategic merger agreement with Espero Pharmaceuticals to establish a combined cardiovascular entity known as Espero BioPharma, effectively ending its standalone operations.
Armetheon has raised $31.3M across 2 funding rounds.
Armetheon has raised $31.3M in total across 2 funding rounds.
Armetheon has raised $31.3M across 2 funding rounds. Most recently, it raised $24.3M Series B in February 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 5, 2015 | $24.3M Series B | Capital TEN, Hercules Bioventures Partners | Larry HSU, Stefan Roever, Amkey Ventures, CDIB Capital Group, ID Softcapital Group | Announced |
| Aug 28, 2014 | $7M Series A | Ashhill Investments, Hercules Bioventures Partners | Larry HSU, Atheneos Capital | Announced |
Armetheon has raised $31.3M in total across 2 funding rounds.
Armetheon's investors include Capital TEN, Hercules BioVentures Partners, Larry Hsu, Stefan Roever, Amkey Ventures, CDIB Capital Group, iD SoftCapital Group, AshHill Investments, Atheneos Capital.